Manhal Izzy, Lisa B. VanWagner, Grace Lin, Mario Altieri, James Y. Findlay, Jae K. Oh, Kymberly D. Watt, Samuel S. Lee, on behalf of The Cirrhotic Cardiomyopathy Consortium – 25 July 2019 – Cirrhotic cardiomyopathy (CCM) is cardiac dysfunction in patients with end‐stage liver disease in the absence of prior heart disease. First defined in 2005 during the World Congress of Gastroenterology, CCM criteria consisted of echocardiographic parameters to identify subclinical cardiac dysfunction in the absence of overt structural abnormalities.

Alcoholic hepatitis has high short-term mortality with limited medical therapeutic options. Liver transplantation remains controversial for this indication given inability of these patients to meet six months of sobriety.

Ramesh Kumar – 24 July 2019

Michael C. Lawrence, Carly M. Darden, Srividya Vasu, Kenjiro Kumano, Jinghua Gu, Xuan Wang, Jinyan Chan, Zhaohui Xu, Benjamin F. Lemoine, Phuong Nguyen, Cynthia Smitherman, Bashoo Naziruddin, Giuliano Testa – 24 July 2019 – The human liver’s capacity to rapidly regenerate to a full‐sized functional organ after resection has allowed successful outcomes for living donor liver transplantation (LDLT) procedures. However, the ability to detect and track physiological changes occurring during liver regeneration after resection and throughout the restoration process is still lacking.

Management of HCV after therapy has complexity if patients continue to engage in high risk activities, are at risk for advanced liver disease progression or have failed first line therapy. In addition, these complexities are especially important to consider as HCV therapy moves outside of subspecialty care. We will utilize a live webinar format that will be recorded for on-demand viewing on Liver Learning ® .Stuart C. Gordon Dr. Gordon is a Professor of Medicine at Wayne State University School of Medicine and Director, Division of Hepatology, at Henry Ford Hospital.

23 July 2019

Michelle A. Camarata, Aftab Ala, Michael L. Schilsky – 23 July 2019 – We evaluate Wilson disease (WD) treatment with zinc acetate (U.S. Food and Drug Administration approved) and alternative zinc salts. Studies examining zinc therapy in WD are few, and data on alternative zinc salts are limited. We describe one of the largest recent studies of zinc therapy in WD.

23 July 2019

23 July 2019

23 July 2019